ADC Therapeutics SA Overview
Pro stress-test →ADC Therapeutics is a commercial-stage biotechnology company pioneering antibody-drug conjugates (ADCs) for cancer treatment. The company has achieved FDA approval for ZYNLONTA, its flagship product targeting relapsed or refractory diffuse large B-cell lymphoma, and maintains a robust pipeline addressing hematological malignancies and solid tumors.
Strategic Profile
Pro stress-test →The company leverages proprietary ADC platform technology with deep oncology expertise to develop highly targeted cancer therapies. ADC Therapeutics operates globally with R&D in London, clinical and commercial operations in New Jersey, and manufacturing/CMC capabilities in the San Francisco Bay Area, positioning itself as a leader in the specialized ADC therapeutic space.
Competitive Landscape
Pro stress-test →ADC Therapeutics competes in the specialized antibody-drug conjugate space against other oncology biotech companies developing targeted cancer therapies. Key competitors include Aura Biosciences and other developers of hematological and solid tumor treatments. ADC Therapeutics differentiates through its validated PBD-based ADC platform, FDA-approved commercial product, and comprehensive pipeline targeting multiple tumor-associated antigens.
Industry Context
ADC Therapeutics SA operates in Biopharmaceuticals / Oncology - Antibody-Drug Conjugates (ADCs).
Key facts
Founded: 2011 · Headquarters: Epalinges, Switzerland · Employees: 263 · Revenue: $185.4M (2023) · Market cap: $518M